Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Denali Therapeutics' Avlayah (tividenofusp alfa-eknm) wins FDA accelerated approval for Hunter syndrome neurologic manifestations
Enzyme replacement therapy, rare disease, Hunter syndrome, mucopolysaccharidosis type II, brain-penetrant therapy - Read more

Corcept Therapeutics' Lifyorli (relacorilant) wins FDA approval for platinum-resistant epithelial ovarian cancer treatment
Small molecule, cancer, glucocorticoid receptor antagonist, ovarian cancer, combination therapy, platinum-resistant - Read more

Biogen, Alteogen partner on subcutaneous delivery tech, $20M upfront, $559M potential milestones
Licensing deal, subcutaneous delivery technology, biologics, milestone payments - Read more

UTSW, InterAct Therapeutics partner on gene therapy platform targeting cancer metastasis through exclusive licensing agreement
Licensing deal, oncology, gene therapy, manufacturing - Read more

Daiichi Sankyo, Tempus AI partner to accelerate ADC development using multimodal foundation models
Research collaboration, oncology, AI/ML, antibody drug conjugate, biomarker discovery - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

BrightGene's BGM0504 (dual GLP-1/GIP agonist) shows up to 8% weight loss in Ph1 obesity studies
Small molecule, metabolic, dual GLP-1/GIP agonist, obesity, oral administration - Read more

Novo Nordisk's UBT251 triple agonist targeting GLP-1/GIP/glucagon advances to Ph3 for type 2 diabetes in China
Protein therapy, metabolic, triple agonist, type 2 diabetes, GLP-1 receptor agonist - Read more

Sarepta Therapeutics reports positive Ph1/2 results for SRP-1001 and SRP-1003 siRNA therapies targeting rare muscular dystrophies
RNAi therapy, rare disease, siRNA, muscular dystrophy, DUX4 target - Read more

Beam Therapeutics' BEAM-302 shows positive Ph1/2 results for alpha-1 antitrypsin deficiency treatment
Gene therapy, rare disease, base editing, alpha-1 antitrypsin deficiency, liver disease - Read more

Clover Biopharmaceuticals reports positive Ph1 data for SCB-1019 respiratory syncytial virus re-vaccination in older adults
Vaccine, infectious disease, protein vaccine, RSV, combination vaccine, re-vaccination - Read more

Endogenex raises $50M venture funding for intestinal diabetes procedure FDA development
Diabetes, medical device, minimally invasive procedure, clinical-stage - Read more

Apogee Therapeutics raises $350M public offering, clinical-stage inflammatory/immunology biologics
Inflammatory and immunology, clinical-stage, biologics, autoimmune - Read more

Amani Therapeutics raises $25M Series A, developing treatments for neuropsychiatric disorders
Neuropsychiatric, small molecule, clinical-stage, schizophrenia - Read more

Vaxess Technologies raises $50M funding, pivot to GLP-1 delivery patches
Microneedle technology, drug delivery platform, GLP-1 delivery, vaccine delivery - Read more [Paywall]

Tenax Therapeutics files $300M mixed shelf offering for general corporate purposes
Pharmaceutical, clinical-stage - Read more

Harrow raises $50M senior notes, ophthalmic disease management solutions provider
Ophthalmology, disease management solutions - Read more

Merck & Co. to acquire Terns Pharmaceuticals for $6.7B, targeting TERN-701 leukemia drug ahead of Keytruda cliff
Small molecule, oncology, strategic, major transaction - Read more

Canadian Institutes of Health Research invests $3M to accelerate primary care research improvements
Healthcare services, primary care, government funding, operational - Read more

Ionis Pharmaceuticals slashes Tryngolza price 93% to $40,000 annually ahead of planned severe hypertriglyceridemia indication expansion
Antisense oligonucleotide, rare disease, strategic, cost reduction, competitive - Read more

Takeda targets $1.3B annual cost savings through sweeping restructuring to fund drug launches and pipeline development
Operational, cost reduction, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Maze Therapeutics reports mixed Ph2 results for MZE829 APOL1 inhibitor in kidney disease treatment
Small molecule, kidney disease, APOL1 inhibitor, focal segmental glomerulosclerosis, proteinuria reduction - Read more

Novartis faces class-action lawsuit over alleged unauthorized sharing of patient data from branded drug websites
Small molecule, oncology, operational, regulatory - Read more

Anavex Life Sciences withdraws EU filing for blarcamesine (ANAVEX 2-73) targeting early Alzheimer's disease after CHMP rejection signal
Small molecule, neurological, Alzheimer's disease, SIGMAR1 receptor, muscarinic receptor - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here